Consilium Wealth Advisory LLC Takes Position in Intuitive Surgical, Inc. $ISRG

Key Points

• Consilium Wealth Advisory LLC purchased a new stake in Intuitive Surgical, acquiring 1,794 shares valued at approximately $975,000 during the second quarter.
• Intuitive Surgical reported $2.19 EPS in its latest quarterly earnings, exceeding analysts' estimates of $1.93, with revenue of $2.44 billion, reflecting a year-over-year growth of 21.4%.
• The stock has a current market capitalization of $162.16 billion and a consensus price target among analysts of $594.19, indicating a moderately positive outlook.

Consilium Wealth Advisory LLC purchased a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,794 shares of the medical equipment provider's stock, valued at approximately $975,000.

A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Intuitive Surgical by 1.4% in the first quarter. Vanguard Group Inc. now owns 32,665,531 shares of the medical equipment provider's stock worth $16,178,258,000 after purchasing an additional 453,335 shares during the last quarter. Invesco Ltd. boosted its holdings in Intuitive Surgical by 1.7% in the first quarter. Invesco Ltd. now owns 4,219,974 shares of the medical equipment provider's stock worth $2,090,027,000 after purchasing an additional 71,794 shares during the last quarter. Northern Trust Corp boosted its holdings in Intuitive Surgical by 0.3% in the first quarter. Northern Trust Corp now owns 3,631,281 shares of the medical equipment provider's stock worth $1,798,465,000 after purchasing an additional 11,988 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Intuitive Surgical by 15.0% in the first quarter. Wellington Management Group LLP now owns 3,499,052 shares of the medical equipment provider's stock worth $1,732,975,000 after purchasing an additional 457,080 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in Intuitive Surgical in the first quarter worth approximately $1,715,899,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

ISRG opened at $452.35 on Friday. The stock has a market capitalization of $162.16 billion, a price-to-earnings ratio of 63.09, a PEG ratio of 4.64 and a beta of 1.61. The company has a fifty day moving average of $463.55 and a 200 day moving average of $500.00. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. During the same period last year, the company posted $1.78 EPS. The business's revenue was up 21.4% on a year-over-year basis. On average, equities research analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on ISRG shares. Erste Group Bank reiterated a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. BTIG Research restated a "buy" rating and set a $571.00 price objective on shares of Intuitive Surgical in a research report on Wednesday. Weiss Ratings restated a "hold (c+)" rating on shares of Intuitive Surgical in a research report on Saturday, September 27th. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Intuitive Surgical in a research report on Friday, August 22nd. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $615.00 price objective on shares of Intuitive Surgical in a research report on Tuesday, August 19th. Fourteen investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $594.19.

Insiders Place Their Bets

In related news, Director Amy L. Ladd sold 336 shares of Intuitive Surgical stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $470.11, for a total transaction of $157,956.96. Following the completion of the sale, the director owned 1,074 shares in the company, valued at $504,898.14. This trade represents a 23.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gary S. Guthart sold 29,360 shares of the company's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the completion of the sale, the insider directly owned 19,827 shares of the company's stock, valued at $9,368,059.23. The trade was a 59.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 45,224 shares of company stock valued at $21,716,492 in the last three months. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.